•
Jun 30, 2021

DexCom Q2 2021 Earnings Report

Dexcom's second quarter performance was characterized by strong financial results and the continued advancement of its key strategic initiatives.

Key Takeaways

Dexcom reported strong second quarter financial results with revenue growth of 32% compared to the same quarter of the prior year, reaching $595.1 million. The company increased its guidance for fiscal year 2021 revenue, Non-GAAP gross profit margin, Non-GAAP operating margin.

Revenue grew 32% versus the same quarter of the prior year to $595.1 million

U.S. revenue growth of 26% and international revenue growth of 58%

GAAP operating income of $101.0 million or 17.0% of revenue, an increase of 200 basis points compared to the second quarter of 2020.

Non-GAAP operating income of $101.5 million or 17.1% of revenue, an increase of 10 basis points over the same quarter of the prior year

Total Revenue
$595M
Previous year: $452M
+31.7%
EPS
$0.19
Previous year: $0.2
-5.0%
Gross margin
70.1%
Previous year: 62.9%
+11.4%
Operating margin
17%
Previous year: 15%
+13.3%
Gross Profit
$417M
Previous year: $284M
+46.8%
Cash and Equivalents
$1.16B
Previous year: $530M
+118.6%
Free Cash Flow
-$39.6M
Previous year: $95.9M
-141.3%
Total Assets
$4.5B
Previous year: $3.52B
+27.9%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

Dexcom is increasing its guidance for fiscal year 2021 revenue, Non-GAAP gross profit margin, Non-GAAP operating margin, and Adjusted EBITDA margin to the following levels:

Positive Outlook

  • Revenue of approximately $2.35 - 2.40 billion (22-25% growth)
  • Non-GAAP Gross Profit Margin of approximately 67%
  • Non-GAAP Operating Margin of approximately 14%
  • Adjusted EBITDA Margin of approximately 24%

Revenue & Expenses

Visualization of income flow from segment revenue to net income